### WHAT IS CLAIMED IS:

1. A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae:

10

ź

$$t$$
-Bu  $t$ -Bu

10

CO<sub>2</sub>CH<sub>3</sub> °CO<sub>2</sub>CH<sub>3</sub> N Me CO<sub>2</sub>CH<sub>3</sub> CO<sub>2</sub>CH<sub>3</sub> t-Bu CO<sub>2</sub>CH<sub>3</sub> CO<sub>2</sub>CH<sub>3</sub> or CO<sub>2</sub>CH<sub>3</sub>

2. A method according to claim 1, comprising administering a compound of the formulae

or

3. A method according to claim 1, comprising administering a compound of the formulae

CO<sub>2</sub>CH<sub>3</sub> CO<sub>2</sub>CH<sub>3</sub> CH3OOC . CH<sub>3</sub>OOC CH3OOC t-Bu

CO<sub>2</sub>CH<sub>3</sub>

10

CO<sub>2</sub>CH<sub>3</sub>

A method according to claim 1, comprising administering a compound 4. of formulae

10

5

5. A method according to claim 1, comprising administering a compound of formulae 15

6. A method according to claim 1, comprising administering a compound of formulae

## 10

## 15

## 7. A method according to claim 1, comprising administering a compound of formulae

$$t$$
-Bu $O$ 
 $CO_2CH_3$ 

or

## 8. A compound of the formulae

t-Bu

CO<sub>2</sub>CH<sub>3</sub>

NH NH NH NH CO<sub>2</sub>CH<sub>3</sub>

$$\begin{array}{c} O \\ NH \\ CO_2CH_3 \end{array}$$

or

5

9. A compound according to claim 8, of the formulae

10. A compound according to claim 8, of the formulae

11. A compound according to claim 8, of the formulae

CO<sub>2</sub>CH<sub>3</sub>

$$t$$
-Bu  $O$   $CO_2CH_3$  or

10

# t-Bu O CO<sub>2</sub>CH<sub>3</sub>

12. A compound according to claim 8, of the formulae

13. A compound according to claim 8, of the formulae

or

10

i-Pr S NH NH S

### 14. A compound according to claim 8, of the formulae

$$\begin{array}{c} O \\ NH \\ NH \\ CO_2CH_3 \end{array}$$

- 10 15. A pharmaceutical composition comprising a compound according to claim 8 and a physiologically acceptable carrier.
  - 16. A pharmaceutical composition comprising a compound according to claim 14 and a physiologically acceptable carrier.
  - 17. A pharmaceutical composition comprising a compound according to claim 8 and a physiologically acceptable carrier, in sterile form.